Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Prime Medicine (Nasdaq: PRME) announced that Allan Reine, M.D., CEO, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco.
A live audio webcast will be available under Events & Presentations on the company's website at www.primemedicine.com, and a replay will remain accessible on the Prime Medicine website for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – PRME
In the Jan 7 session, PRME gained 9.19%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.2% during that session. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Conference appearance | Neutral | -1.9% | Announcement of participation in Evercore healthcare conference with webcast access. |
| Nov 11 | Conference appearance | Neutral | +11.2% | Jefferies healthcare conference fireside chat with webcast and replay details. |
| Nov 07 | Earnings & updates | Negative | -8.8% | Q3 2025 financials with net loss, R&D spend, and program timelines. |
| Nov 07 | Earnings & pipeline | Negative | -8.8% | Q3 2025 results plus IND/CTA timing and 2027 initial clinical data goals. |
| Nov 03 | Leadership change | Neutral | -7.7% | Appointment of new Chief Business Officer to lead business development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent conference appearances and corporate updates have produced mixed single-day price reactions, while earnings and financing-linked updates have coincided with larger negative moves.
Over the last few months, Prime Medicine has combined financing, pipeline, and visibility events. In August 2025, it completed a public equity offering, followed by Q2 and Q3 10‑Q filings detailing ongoing net losses and investment in R&D. Corporate updates in November 2025 included appointing a new Chief Business Officer and releasing Q3 results with cash of $213.3M. Multiple conference appearances in late 2025 mirror today’s J.P. Morgan presentation, underscoring a continued focus on investor and partner outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco, California.
A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the event.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
